{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:35:50Z","timestamp":1794274550703,"version":"4.9.0"},"reference-count":37,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"argenx BV","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,4,24]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aims to explore the impact of myasthenia gravis (MG) \u2014 in terms of treatments, side effects, comorbidities, psychological health and work or study\u2014 in the real world from a patient perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and participants<\/jats:title>\n                    <jats:p>This is a prospective, observational, digital, longitudinal study. Adults diagnosed with MG residing in the USA, Japan, Germany, the UK, Italy, Spain or Canada were eligible to participate in the study. There were no other exclusion criteria. Participants used a bespoke smartphone application to confirm eligibility, provide consent and enter data about their MG into a profile, a tracker to record MG-related events and a series of patient-reported outcome instruments. 1693 participants completed at least 1 survey and were included in this analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results are presented as a percentage of respondents to each survey question. The study population was largely female (69% of 1586 respondents), with an average age of 49.9 years (SD 14.8). In the previous 12 months, 83.7% of 1412 respondents confirmed that they had received one or more routine treatments for MG, and 67.1% of 255 respondents confirmed that they had experienced a side effect in the previous month. Commonly experienced comorbidities reported by 966 respondents were thyroid problems, hypertension and anxiety, experienced by 37.5%, 31.4% and 28.0% of respondents, respectively.<\/jats:p>\n                    <jats:p>According to 889 respondents to the Hospital Anxiety and Depression Scale survey, 52.7% and 43.2% had a score indicative of at least mild anxiety and mild depression, respectively. Of 257 respondents, 33.0% reported experiencing a work or study impact in the past month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis of baseline characteristics of the MyRealWorld MG study population indicates that, despite current treatments, patients experience notable burden. Further scheduled analyses will develop a longitudinal picture of MG burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04176211\">NCT04176211<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-068104","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T10:16:14Z","timestamp":1683800174000},"page":"e068104","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG)"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04176211","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sonia","family":"Berrih-Aknin","sequence":"first","affiliation":[{"name":"INSERM, Institute of Myology, Center of Research in Myology, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurology, John Radcliffe Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuroscience Clinical Research Center, Charite Universitatsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl G","family":"Claeys","sequence":"additional","affiliation":[{"name":"Department of Neurology, KU Leuven University Hospitals, Leuven, Belgium"},{"name":"Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Muppidi","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosciences, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[{"name":"Department of DNSRO, University of Naples Federico II, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-3276","authenticated-orcid":false,"given":"Fatemeh","family":"Amini","sequence":"additional","affiliation":[{"name":"Vitaccess Limited, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Larkin","sequence":"additional","affiliation":[{"name":"Vitaccess Limited, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Quinn","sequence":"additional","affiliation":[{"name":"Vitaccess Limited, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Beauchamp","sequence":"additional","affiliation":[{"name":"Argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Philips","sequence":"additional","affiliation":[{"name":"Argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"De Ruyck","sequence":"additional","affiliation":[{"name":"Argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Paci","sequence":"additional","affiliation":[{"name":"Argenx BV, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"2025121400113775000_13.5.e068104.1","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis"},{"key":"2025121400113775000_13.5.e068104.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025121400113775000_13.5.e068104.3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894"},{"key":"2025121400113775000_13.5.e068104.4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali","year":"2008","journal-title":"Neurology"},{"key":"2025121400113775000_13.5.e068104.5","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.063404"},{"key":"2025121400113775000_13.5.e068104.6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jocn.2018.01.011","article-title":"Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis","volume":"50","author":"Braz","year":"2018","journal-title":"J Clin Neurosci"},{"key":"2025121400113775000_13.5.e068104.7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10072-009-0167-y","article-title":"Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis","volume":"31","author":"Raggi","year":"2010","journal-title":"Neurol Sci"},{"key":"2025121400113775000_13.5.e068104.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"2025121400113775000_13.5.e068104.9","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24213"},{"key":"2025121400113775000_13.5.e068104.10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","article-title":"The lived experience of myasthenia gravis: a patient-led analysis","volume":"10","author":"Law","year":"2021","journal-title":"Neurol Ther"},{"key":"2025121400113775000_13.5.e068104.11","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2025121400113775000_13.5.e068104.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60872-7"},{"key":"2025121400113775000_13.5.e068104.13","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pds.4962","article-title":"Use of real-world evidence in regulatory decisions for rare diseases in the United states-current status and future directions","volume":"29","author":"Wu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121400113775000_13.5.e068104.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048198","article-title":"Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (myrealworld Mg)","volume":"11","author":"Berrih-Aknin","year":"2021","journal-title":"BMJ Open"},{"key":"2025121400113775000_13.5.e068104.15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140"},{"key":"2025121400113775000_13.5.e068104.16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"2025121400113775000_13.5.e068104.17","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053"},{"key":"2025121400113775000_13.5.e068104.18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mus.25198","article-title":"International Clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-qol15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"2025121400113775000_13.5.e068104.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(00)00102-1"},{"key":"2025121400113775000_13.5.e068104.20","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S8915"},{"key":"2025121400113775000_13.5.e068104.21","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00538","article-title":"Novel treatments in myasthenia gravis","volume":"11","author":"Menon","year":"2020","journal-title":"Front Neurol"},{"key":"2025121400113775000_13.5.e068104.22","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0810"},{"key":"2025121400113775000_13.5.e068104.23","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/815038"},{"key":"2025121400113775000_13.5.e068104.24","doi-asserted-by":"crossref","unstructured":"Mehndiratta MM , Pandey S , Kuntzer T , et al . Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database of Syst Rev 2014. doi:10.1002\/14651858.CD006986.pub3","DOI":"10.1002\/14651858.CD006986.pub3"},{"key":"2025121400113775000_13.5.e068104.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"2025121400113775000_13.5.e068104.26","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"2025121400113775000_13.5.e068104.27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3889\/oamjms.2018.110","article-title":"Myasthenia gravis and associated diseases","volume":"6","author":"Tanovska","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"2025121400113775000_13.5.e068104.28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117549","article-title":"Comorbidities worsen the prognosis of generalized myasthenia gravis post-thymectomy","volume":"427","author":"Laakso","year":"2021","journal-title":"J Neurol Sci"},{"key":"2025121400113775000_13.5.e068104.29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025121400113775000_13.5.e068104.30","article-title":"A review of psychiatric comorbidity in myasthenia gravis","volume":"12","author":"Law","year":"2020","journal-title":"Cureus"},{"key":"2025121400113775000_13.5.e068104.31","unstructured":"World Health Organization . Depression and other common mental disorders: global health estimates. 2017. Available: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf"},{"key":"2025121400113775000_13.5.e068104.32","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00481","article-title":"Risk of depressive disorders following myasthenia gravis: a nationwide population-based retrospective cohort study","volume":"10","author":"Chu","year":"2019","journal-title":"Front Psychiatry"},{"key":"2025121400113775000_13.5.e068104.33","first-page":"482","article-title":"Psychopathology, psychosocial factors and quality of life in patients with myasthenia gravis","volume":"33","author":"Kotan","year":"2016","journal-title":"J Neurol Sci"},{"key":"2025121400113775000_13.5.e068104.34","doi-asserted-by":"crossref","first-page":"II90","DOI":"10.1007\/s00415-007-2022-5","article-title":"Psychosocial aspects in patients with myasthenia gravis","volume":"254","author":"K\u00f6hler","year":"2007","journal-title":"J Neurol"},{"key":"2025121400113775000_13.5.e068104.35","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15040722","article-title":"Factors related to unemployment in Europe. A cross-sectional study from the courage survey in Finland, Poland and Spain","volume":"15","author":"Leonardi","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"2025121400113775000_13.5.e068104.36","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200009)23:9<1402::AID-MUS11>3.0.CO;2-B"},{"key":"2025121400113775000_13.5.e068104.37","article-title":"Myasthenia gravis and its association with thyroid diseases","volume":"12","author":"Amin","year":"2020","journal-title":"Cureus"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-068104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:11:49Z","timestamp":1765699909000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-068104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,11]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-068104"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-068104","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2022-068104.supp1","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}